Zhejiang Starry PharmaceuticalLtd (603520) Stock Overview
Engages in the research, development, production, and sale of active pharmaceutical ingredients in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
603520 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Zhejiang Starry Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.66 |
| 52 Week High | CN¥14.37 |
| 52 Week Low | CN¥7.89 |
| Beta | 0.49 |
| 1 Month Change | -20.26% |
| 3 Month Change | -28.31% |
| 1 Year Change | -22.12% |
| 3 Year Change | -43.06% |
| 5 Year Change | -69.69% |
| Change since IPO | 35.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603520 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 8.3% | 1.9% | 0.1% |
| 1Y | -22.1% | -17.8% | 9.3% |
Return vs Industry: 603520 underperformed the CN Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: 603520 underperformed the CN Market which returned 7.3% over the past year.
Price Volatility
| 603520 volatility | |
|---|---|
| 603520 Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 4.4% |
Stable Share Price: 603520 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603520's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 1,905 | Weiyi Shen | www.starrypharm.com |
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iodine-methyl, iodophorol, ioflufenicol, iopromide gadoxime meglumine, gadolinate dimeglumine, gadolinium, and iohexol injections; contrast agent APIs and intermediates consisting of iohexol, iopamidol, iodixanol, iodimeperidine, iopromide, iodophorol, iodophorol hydrolysate, iohexol hydrolysate, gadobacterium meglumine iodide, and triiodoisophthaloyl chloride esters; levofloxacin hydrochloride, levofloxacin, levofluorocycloester, and levofluorocarboxylic acid; and CMO and CDMO series, including loxoprofen sodium, loxoprofen acid, trimethyliodosilane, 2-iodo-5-methylbenzoic acid, methyl o-iodobenzoate, and iodobenzene.
Zhejiang Starry Pharmaceutical Co.,Ltd. Fundamentals Summary
| 603520 fundamental statistics | |
|---|---|
| Market cap | CN¥3.80b |
| Earnings (TTM) | CN¥16.84m |
| Revenue (TTM) | CN¥2.47b |
Is 603520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603520 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.47b |
| Cost of Revenue | CN¥1.96b |
| Gross Profit | CN¥508.73m |
| Other Expenses | CN¥491.89m |
| Earnings | CN¥16.84m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 31, 2026
| Earnings per share (EPS) | 0.038 |
| Gross Margin | 20.59% |
| Net Profit Margin | 0.68% |
| Debt/Equity Ratio | 114.9% |
How did 603520 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/31 04:09 |
| End of Day Share Price | 2026/07/31 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zhejiang Starry Pharmaceutical Co.,Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Dai | Huatai Research |
| Song Yang | Tianfeng Securities Brokerage Co., Ltd |
| Tielin Chen | Topsperity Securities |